InvestorsHub Logo
Followers 8
Posts 609
Boards Moderated 0
Alias Born 10/15/2009

Re: None

Friday, 04/24/2015 1:23:53 PM

Friday, April 24, 2015 1:23:53 PM

Post# of 2098
SAN DIEGO , April 24, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, announced today that it has closed the sale of its Zohydro® ER (hydrocodone bitartrate) business to a wholly-owned subsidiary of Pernix Therapeutics Holdings, Inc. (Nasdaq:PTX) for $80 million in cash, approximately 1.68 million shares of Pernix common stock, plus regulatory and sales milestones of up to $283.5 million .